Literature DB >> 10583442

The growth and the control of human immunodeficiency virus in the lung: implications for highly active antiretroviral therapy.

N C White1, C Agostini, D Israel-Biet, G Semenzato, J R Clarke.   

Abstract

In recent years, it has become apparent that the lung is an important niche for the proliferation of human immunodeficiency virus (HIV), which may have implications for highly active antiretroviral therapy (HAART). The lung itself is a major site for the opportunistic infections associated with the progression to acquired immune deficiency syndrome (AIDS), specifically Pneumocystis carinii, Myobacterium tuberculosis and pyogenic bacteria. These cases of active pulmonary complications are direct indicators of enhanced progression to AIDS-defining illness and increased morbidity and mortality. It is therefore essential that the interaction between the lung and HIV is fully understood. Recent research indicates the lung may be a major sanctuary for the virus, with distinct evolution and replication in contrast to other target organs for HIV. In this review, we will discuss the recent findings of HIV infection, evolution, host factors involved in the control of HIV within the lung and the impact this may have on current therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10583442     DOI: 10.1046/j.1365-2362.1999.00550.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  11 in total

Review 1.  The immunocompromised host: HIV infection.

Authors:  James M Beck
Journal:  Proc Am Thorac Soc       Date:  2005

2.  Effect of bacterial pneumonia on lung simian immunodeficiency virus (SIV) replication in alcohol consuming SIV-infected rhesus macaques.

Authors:  Steve Nelson; Kyle I Happel; Ping Zhang; Leann Myers; Jason P Dufour; Gregory J Bagby
Journal:  Alcohol Clin Exp Res       Date:  2013-02-15       Impact factor: 3.455

3.  Transport of HIV-protease inhibitors across 1 alpha,25di-hydroxy vitamin D3-treated Calu-3 cell monolayers: modulation of P-glycoprotein activity.

Authors:  Jignesh Patel; Dhananjay Pal; Veena Vangal; Mohit Gandhi; Ashim L Mitra
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

4.  Proteomic landscape of bronchoalveolar lavage fluid in human immunodeficiency virus infection.

Authors:  Elizabeth V Nguyen; Sina A Gharib; Kristina Crothers; Yu-Hua Chow; David R Park; David R Goodlett; Lynn M Schnapp
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-11-08       Impact factor: 5.464

5.  Antigenic stimulation specifically reactivates the replication of archived simian immunodeficiency virus genomes in chronically infected macaques.

Authors:  Céline Renoux; Simon Wain-Hobson; Bruno Hurtrel; Rémi Cheynier
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  Up-regulation of alveolar macrophage matrix metalloproteinases in HIV1(+) smokers with early emphysema.

Authors:  Robert J Kaner; Francisco Santiago; Ronald G Crystal
Journal:  J Leukoc Biol       Date:  2009-07-15       Impact factor: 4.962

Review 7.  Human Immunodeficiency Virus Infection and Host Defense in the Lungs.

Authors:  Tysheena P Charles; Judd E Shellito
Journal:  Semin Respir Crit Care Med       Date:  2016-03-14       Impact factor: 3.119

Review 8.  Abnormalities in host defense associated with HIV infection.

Authors:  James M Beck
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

9.  Adenovirus vectors block human immunodeficiency virus-1 replication in human alveolar macrophages by inhibition of the long terminal repeat.

Authors:  Robert J Kaner; Francisco Santiago; Franck Rahaghi; Elizabeth Michaels; John P Moore; Ronald G Crystal
Journal:  Am J Respir Cell Mol Biol       Date:  2009-10-05       Impact factor: 6.914

Review 10.  Recent 5-year Findings and Technological Advances in the Proteomic Study of HIV-associated Disorders.

Authors:  Lijun Zhang; Xiaofang Jia; Jun-O Jin; Hongzhou Lu; Zhimi Tan
Journal:  Genomics Proteomics Bioinformatics       Date:  2017-04-06       Impact factor: 7.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.